Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer’s Disease

Recent studies have demonstrated the high analytical and diagnostic performance of plasma p-tau217 using well-defined cohorts. We aimed to assess the analytical, diagnostic, and prognostic utility of plasma p-tau217 as a routine biomarker in symptomatic patients attending our memory clinic. We also sought to identify optimal cutoff points that align with cerebrospinal fluid (CSF) amyloid beta (Aβ) status. A total of 276 cognitively impaired patients were included, with 81 mild cognitive impairment (MCI) patients followed for a mean of 56 (±15.8) months to evaluate progression to Alzheimer’s disease (AD). CSF and blood biomarkers of AD were quantified using the Lumipulse G platform. Plasma p-tau217 levels showed strong correlations with CSF Aβ42/Aβ40 (r = −0.707), p-tau181/Aβ42 (r = 0.842), and p-tau181 (r = 0.728). Plasma p-tau217 levels were significantly higher in the A + T + group than in A − T +/− (p < 0.001) and outperformed other plasma markers in detecting CSF Aβ pathology (AUC 0.924).Additionally, p-tau217 moderated cognitive changes over time as measured by the Mini-mental state examination (MMSE) (F(2, 70) = 13.995, p < 0.001) and outperformed other plasma biomarkers in predicting progression from MCI to AD (AUC 0.876). Using a dual cutoff strategy, 72% of patients were classified with 94.9% concordance with CSF Aβ status. Plasma p-tau217 shows strong potential as a non-invasive, cost-effective diagnostic and prognostic tool in clinical settings.